Roche's SMA drug trial win bolsters $2 billion sales prospects
Reuters India -

Roche's spinal muscular atrophy (SMA) drug risdiplam hit another clinical trial target, the Swiss drugmaker said on Thursday, which analysts said bolsters its prospects of reaching $2 billion in annual sales.

Read this story at

Loading...

Related Articles